- An EUA for ARCT-154 as a COVID-19 vaccine in Vietnam has been submitted, with expected approval in 2022.
- A phase 2 study using ARCT-810 as a treatment option for patients with OTC deficiency is expected to start in mid-2022; results are then expected 2nd half of 2022.
- A CTA to begin a study using ARCT-032 for the treatment of patients with Cystic Fibrosis is expected Q3 of 2022.
- Arcturus had $319.7 million in cash as of March 31, 2022; enough cash to fund operations into late 2023.
For further details see:
Arcturus: Potential Based On Rare Disease Therapy ARCT-810